nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—BMPR1B—prostate cancer	0.18	0.45	CbGaD
Pazopanib—FGFR2—prostate cancer	0.0863	0.216	CbGaD
Pazopanib—PDGFRB—prostate cancer	0.0682	0.171	CbGaD
Pazopanib—KDR—prostate cancer	0.0517	0.129	CbGaD
Pazopanib—SLCO1B1—Cabazitaxel—prostate cancer	0.0166	0.0568	CbGbCtD
Pazopanib—SLCO1B1—Estrone—prostate cancer	0.0162	0.0555	CbGbCtD
Pazopanib—CYP3A4—prostate cancer	0.0135	0.0338	CbGaD
Pazopanib—UGT1A1—Estradiol—prostate cancer	0.0135	0.0461	CbGbCtD
Pazopanib—ABCG2—Cabazitaxel—prostate cancer	0.0132	0.0451	CbGbCtD
Pazopanib—ABCG2—Estrone—prostate cancer	0.0129	0.0441	CbGbCtD
Pazopanib—CYP2C8—Nilutamide—prostate cancer	0.0115	0.0392	CbGbCtD
Pazopanib—SLCO1B1—Conjugated Estrogens—prostate cancer	0.0106	0.0363	CbGbCtD
Pazopanib—CYP2C8—Abiraterone—prostate cancer	0.0095	0.0325	CbGbCtD
Pazopanib—SLCO1B1—Estradiol—prostate cancer	0.00932	0.0319	CbGbCtD
Pazopanib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00885	0.0303	CbGbCtD
Pazopanib—UGT1A1—Etoposide—prostate cancer	0.00879	0.0301	CbGbCtD
Pazopanib—ABCG2—Conjugated Estrogens—prostate cancer	0.00843	0.0289	CbGbCtD
Pazopanib—ABCG2—Mitoxantrone—prostate cancer	0.00767	0.0262	CbGbCtD
Pazopanib—ABCG2—Estradiol—prostate cancer	0.0074	0.0253	CbGbCtD
Pazopanib—CYP1A2—Flutamide—prostate cancer	0.00735	0.0252	CbGbCtD
Pazopanib—CYP2D6—Bicalutamide—prostate cancer	0.00731	0.025	CbGbCtD
Pazopanib—ABCB1—Estramustine—prostate cancer	0.00721	0.0247	CbGbCtD
Pazopanib—CYP2C8—Cabazitaxel—prostate cancer	0.00703	0.024	CbGbCtD
Pazopanib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00612	0.0209	CbGbCtD
Pazopanib—CYP2D6—Abiraterone—prostate cancer	0.00606	0.0207	CbGbCtD
Pazopanib—CYP1A2—Estrone—prostate cancer	0.00532	0.0182	CbGbCtD
Pazopanib—ABCG2—Etoposide—prostate cancer	0.00483	0.0165	CbGbCtD
Pazopanib—ABCB1—Cabazitaxel—prostate cancer	0.00476	0.0163	CbGbCtD
Pazopanib—CYP3A4—Bicalutamide—prostate cancer	0.00465	0.0159	CbGbCtD
Pazopanib—ABCB1—Estrone—prostate cancer	0.00465	0.0159	CbGbCtD
Pazopanib—ABCG2—Docetaxel—prostate cancer	0.00442	0.0151	CbGbCtD
Pazopanib—CYP3A4—Estramustine—prostate cancer	0.00432	0.0148	CbGbCtD
Pazopanib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00414	0.0142	CbGbCtD
Pazopanib—CYP2C8—Estradiol—prostate cancer	0.00394	0.0135	CbGbCtD
Pazopanib—CYP3A4—Flutamide—prostate cancer	0.00385	0.0132	CbGbCtD
Pazopanib—CYP3A4—Abiraterone—prostate cancer	0.00385	0.0132	CbGbCtD
Pazopanib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00348	0.0119	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—prostate cancer	0.0033	0.0113	CbGbCtD
Pazopanib—CYP1A2—Estradiol—prostate cancer	0.00305	0.0104	CbGbCtD
Pazopanib—ABCB1—Conjugated Estrogens—prostate cancer	0.00304	0.0104	CbGbCtD
Pazopanib—CYP3A4—Cabazitaxel—prostate cancer	0.00285	0.00975	CbGbCtD
Pazopanib—CYP3A4—Estrone—prostate cancer	0.00279	0.00953	CbGbCtD
Pazopanib—ABCB1—Mitoxantrone—prostate cancer	0.00276	0.00946	CbGbCtD
Pazopanib—ABCB1—Estradiol—prostate cancer	0.00267	0.00914	CbGbCtD
Pazopanib—CYP2C8—Etoposide—prostate cancer	0.00258	0.00881	CbGbCtD
Pazopanib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00248	0.00849	CbGbCtD
Pazopanib—ABCB1—Prednisone—prostate cancer	0.0023	0.00786	CbGbCtD
Pazopanib—CYP1A2—Etoposide—prostate cancer	0.00199	0.00682	CbGbCtD
Pazopanib—PDGFRA—penis—prostate cancer	0.00188	0.0287	CbGeAlD
Pazopanib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00182	0.00623	CbGbCtD
Pazopanib—ABCB1—Etoposide—prostate cancer	0.00174	0.00596	CbGbCtD
Pazopanib—CYP3A4—Mitoxantrone—prostate cancer	0.00166	0.00567	CbGbCtD
Pazopanib—CYP3A4—Estradiol—prostate cancer	0.0016	0.00547	CbGbCtD
Pazopanib—ABCB1—Docetaxel—prostate cancer	0.00159	0.00546	CbGbCtD
Pazopanib—CYP3A4—Prednisone—prostate cancer	0.00138	0.00471	CbGbCtD
Pazopanib—UGT1A1—urine—prostate cancer	0.00119	0.0182	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—prostate cancer	0.00119	0.00407	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—prostate cancer	0.00112	0.00383	CbGbCtD
Pazopanib—ITK—prostate gland—prostate cancer	0.0011	0.0168	CbGeAlD
Pazopanib—CYP3A4—Etoposide—prostate cancer	0.00104	0.00357	CbGbCtD
Pazopanib—TAOK1—prostate gland—prostate cancer	0.001	0.0153	CbGeAlD
Pazopanib—MAP3K9—epithelium—prostate cancer	0.000978	0.015	CbGeAlD
Pazopanib—CYP3A4—Docetaxel—prostate cancer	0.000956	0.00327	CbGbCtD
Pazopanib—SH2B3—prostate gland—prostate cancer	0.000941	0.0144	CbGeAlD
Pazopanib—STK16—prostate gland—prostate cancer	0.0008	0.0122	CbGeAlD
Pazopanib—SH2B3—seminal vesicle—prostate cancer	0.000796	0.0122	CbGeAlD
Pazopanib—FGFR3—prostate gland—prostate cancer	0.000788	0.0121	CbGeAlD
Pazopanib—RIOK2—prostate gland—prostate cancer	0.000788	0.0121	CbGeAlD
Pazopanib—BMPR1B—prostate gland—prostate cancer	0.00078	0.0119	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—prostate cancer	0.000712	0.00244	CbGbCtD
Pazopanib—STK36—prostate gland—prostate cancer	0.000708	0.0108	CbGeAlD
Pazopanib—PI4KB—prostate gland—prostate cancer	0.000697	0.0107	CbGeAlD
Pazopanib—LIMK2—prostate gland—prostate cancer	0.000684	0.0105	CbGeAlD
Pazopanib—TAOK1—renal system—prostate cancer	0.000681	0.0104	CbGeAlD
Pazopanib—TAOK1—urethra—prostate cancer	0.000669	0.0102	CbGeAlD
Pazopanib—RIOK2—seminal vesicle—prostate cancer	0.000666	0.0102	CbGeAlD
Pazopanib—Rilpivirine—CYP2C19—prostate cancer	0.000649	0.611	CrCbGaD
Pazopanib—SH2B3—urethra—prostate cancer	0.00063	0.00964	CbGeAlD
Pazopanib—FLT4—prostate gland—prostate cancer	0.000615	0.00941	CbGeAlD
Pazopanib—PIP4K2C—prostate gland—prostate cancer	0.000611	0.00936	CbGeAlD
Pazopanib—FGFR1—prostate gland—prostate cancer	0.000606	0.00928	CbGeAlD
Pazopanib—STK36—seminal vesicle—prostate cancer	0.000598	0.00916	CbGeAlD
Pazopanib—PI4KB—seminal vesicle—prostate cancer	0.000589	0.00902	CbGeAlD
Pazopanib—MAP3K9—testis—prostate cancer	0.000587	0.00898	CbGeAlD
Pazopanib—MAP3K2—prostate gland—prostate cancer	0.00058	0.00887	CbGeAlD
Pazopanib—FGFR3—epithelium—prostate cancer	0.000579	0.00886	CbGeAlD
Pazopanib—BMPR1B—epithelium—prostate cancer	0.000573	0.00877	CbGeAlD
Pazopanib—ITK—bone marrow—prostate cancer	0.000566	0.00866	CbGeAlD
Pazopanib—FGF1—prostate gland—prostate cancer	0.000546	0.00836	CbGeAlD
Pazopanib—LCK—prostate gland—prostate cancer	0.000543	0.00831	CbGeAlD
Pazopanib—FGFR3—renal system—prostate cancer	0.000537	0.00822	CbGeAlD
Pazopanib—RIOK2—urethra—prostate cancer	0.000527	0.00807	CbGeAlD
Pazopanib—FGFR3—urethra—prostate cancer	0.000527	0.00807	CbGeAlD
Pazopanib—CYP1A2—urine—prostate cancer	0.000527	0.00806	CbGeAlD
Pazopanib—PIP4K2C—seminal vesicle—prostate cancer	0.000517	0.00791	CbGeAlD
Pazopanib—FGFR2—prostate gland—prostate cancer	0.000516	0.00789	CbGeAlD
Pazopanib—TAOK1—bone marrow—prostate cancer	0.000515	0.00788	CbGeAlD
Pazopanib—SH2B3—bone marrow—prostate cancer	0.000485	0.00742	CbGeAlD
Pazopanib—ITK—testis—prostate cancer	0.000484	0.0074	CbGeAlD
Pazopanib—FLT1—prostate gland—prostate cancer	0.000478	0.00731	CbGeAlD
Pazopanib—PI4KB—renal system—prostate cancer	0.000475	0.00727	CbGeAlD
Pazopanib—STK36—urethra—prostate cancer	0.000474	0.00725	CbGeAlD
Pazopanib—EPHB6—prostate gland—prostate cancer	0.000472	0.00723	CbGeAlD
Pazopanib—PI4KB—urethra—prostate cancer	0.000466	0.00714	CbGeAlD
Pazopanib—STK10—prostate gland—prostate cancer	0.000452	0.00692	CbGeAlD
Pazopanib—FLT4—epithelium—prostate cancer	0.000452	0.00691	CbGeAlD
Pazopanib—TAOK3—prostate gland—prostate cancer	0.000451	0.0069	CbGeAlD
Pazopanib—PDGFRA—prostate gland—prostate cancer	0.000448	0.00685	CbGeAlD
Pazopanib—TAOK1—testis—prostate cancer	0.00044	0.00674	CbGeAlD
Pazopanib—PLK4—bone marrow—prostate cancer	0.000437	0.00668	CbGeAlD
Pazopanib—UGT1A1—prostate gland—prostate cancer	0.000427	0.00654	CbGeAlD
Pazopanib—MAP3K9—lymph node—prostate cancer	0.000425	0.00651	CbGeAlD
Pazopanib—SH2B3—testis—prostate cancer	0.000415	0.00634	CbGeAlD
Pazopanib—Rilpivirine—CYP3A4—prostate cancer	0.000413	0.389	CrCbGaD
Pazopanib—PIP4K2C—urethra—prostate cancer	0.000409	0.00626	CbGeAlD
Pazopanib—AURKC—testis—prostate cancer	0.000408	0.00625	CbGeAlD
Pazopanib—FGFR1—urethra—prostate cancer	0.000406	0.00621	CbGeAlD
Pazopanib—RIOK2—bone marrow—prostate cancer	0.000406	0.00621	CbGeAlD
Pazopanib—FLT1—seminal vesicle—prostate cancer	0.000404	0.00619	CbGeAlD
Pazopanib—KDR—prostate gland—prostate cancer	0.000404	0.00618	CbGeAlD
Pazopanib—MAP2K5—prostate gland—prostate cancer	0.000404	0.00618	CbGeAlD
Pazopanib—FGF1—epithelium—prostate cancer	0.000401	0.00614	CbGeAlD
Pazopanib—EPHB6—seminal vesicle—prostate cancer	0.0004	0.00612	CbGeAlD
Pazopanib—CSF1R—prostate gland—prostate cancer	0.000394	0.00603	CbGeAlD
Pazopanib—FGFR2—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000389	0.179	CbGdCrCtD
Pazopanib—CYP3A4—urine—prostate cancer	0.000381	0.00584	CbGeAlD
Pazopanib—TAOK3—seminal vesicle—prostate cancer	0.000381	0.00583	CbGeAlD
Pazopanib—FGFR2—epithelium—prostate cancer	0.000379	0.0058	CbGeAlD
Pazopanib—CYP2D6—urine—prostate cancer	0.000375	0.00574	CbGeAlD
Pazopanib—PLK4—testis—prostate cancer	0.000373	0.00571	CbGeAlD
Pazopanib—FGF1—renal system—prostate cancer	0.000372	0.0057	CbGeAlD
Pazopanib—LCK—urethra—prostate cancer	0.000363	0.00556	CbGeAlD
Pazopanib—PI4KB—bone marrow—prostate cancer	0.000359	0.0055	CbGeAlD
Pazopanib—KIT—prostate gland—prostate cancer	0.000358	0.00548	CbGeAlD
Pazopanib—STK16—testis—prostate cancer	0.000352	0.00539	CbGeAlD
Pazopanib—FGFR2—renal system—prostate cancer	0.000351	0.00538	CbGeAlD
Pazopanib—FLT1—epithelium—prostate cancer	0.000351	0.00537	CbGeAlD
Pazopanib—ITK—lymph node—prostate cancer	0.000351	0.00537	CbGeAlD
Pazopanib—PDGFRB—prostate gland—prostate cancer	0.00035	0.00535	CbGeAlD
Pazopanib—FGFR3—testis—prostate cancer	0.000347	0.00531	CbGeAlD
Pazopanib—RIOK2—testis—prostate cancer	0.000347	0.00531	CbGeAlD
Pazopanib—MAP3K19—testis—prostate cancer	0.000344	0.00526	CbGeAlD
Pazopanib—BMPR1B—testis—prostate cancer	0.000344	0.00526	CbGeAlD
Pazopanib—KDR—seminal vesicle—prostate cancer	0.000342	0.00523	CbGeAlD
Pazopanib—MAP2K5—seminal vesicle—prostate cancer	0.000342	0.00523	CbGeAlD
Pazopanib—CSF1R—seminal vesicle—prostate cancer	0.000333	0.0051	CbGeAlD
Pazopanib—FGFR2—Estradiol—Estramustine—prostate cancer	0.00033	0.153	CbGdCrCtD
Pazopanib—FLT1—renal system—prostate cancer	0.000326	0.00499	CbGeAlD
Pazopanib—FLT1—urethra—prostate cancer	0.00032	0.0049	CbGeAlD
Pazopanib—TAOK1—lymph node—prostate cancer	0.000319	0.00488	CbGeAlD
Pazopanib—FLT4—bone marrow—prostate cancer	0.000317	0.00485	CbGeAlD
Pazopanib—EPHB6—urethra—prostate cancer	0.000316	0.00484	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—prostate cancer	0.000315	0.00482	CbGeAlD
Pazopanib—STK36—testis—prostate cancer	0.000312	0.00477	CbGeAlD
Pazopanib—STK10—renal system—prostate cancer	0.000308	0.00472	CbGeAlD
Pazopanib—TAOK3—renal system—prostate cancer	0.000307	0.0047	CbGeAlD
Pazopanib—PI4KB—testis—prostate cancer	0.000307	0.0047	CbGeAlD
Pazopanib—PDGFRA—renal system—prostate cancer	0.000305	0.00467	CbGeAlD
Pazopanib—KIT—seminal vesicle—prostate cancer	0.000303	0.00463	CbGeAlD
Pazopanib—TAOK3—urethra—prostate cancer	0.000302	0.00462	CbGeAlD
Pazopanib—LIMK2—testis—prostate cancer	0.000301	0.00461	CbGeAlD
Pazopanib—SH2B3—lymph node—prostate cancer	0.0003	0.0046	CbGeAlD
Pazopanib—MAP3K2—bone marrow—prostate cancer	0.000299	0.00457	CbGeAlD
Pazopanib—KDR—epithelium—prostate cancer	0.000297	0.00454	CbGeAlD
Pazopanib—AURKC—lymph node—prostate cancer	0.000296	0.00453	CbGeAlD
Pazopanib—PDGFRB—seminal vesicle—prostate cancer	0.000296	0.00453	CbGeAlD
Pazopanib—UGT1A1—renal system—prostate cancer	0.000291	0.00446	CbGeAlD
Pazopanib—LCK—bone marrow—prostate cancer	0.00028	0.00428	CbGeAlD
Pazopanib—KDR—renal system—prostate cancer	0.000275	0.00421	CbGeAlD
Pazopanib—FLT4—testis—prostate cancer	0.000271	0.00414	CbGeAlD
Pazopanib—PLK4—lymph node—prostate cancer	0.000271	0.00414	CbGeAlD
Pazopanib—KDR—urethra—prostate cancer	0.000271	0.00414	CbGeAlD
Pazopanib—MAP2K5—urethra—prostate cancer	0.000271	0.00414	CbGeAlD
Pazopanib—PIP4K2C—testis—prostate cancer	0.000269	0.00412	CbGeAlD
Pazopanib—FGFR1—testis—prostate cancer	0.000267	0.00409	CbGeAlD
Pazopanib—CSF1R—urethra—prostate cancer	0.000264	0.00404	CbGeAlD
Pazopanib—KIT—epithelium—prostate cancer	0.000263	0.00403	CbGeAlD
Pazopanib—FGFR2—Estradiol—Estrone—prostate cancer	0.000262	0.121	CbGdCrCtD
Pazopanib—PDGFRB—epithelium—prostate cancer	0.000257	0.00393	CbGeAlD
Pazopanib—STK16—lymph node—prostate cancer	0.000256	0.00391	CbGeAlD
Pazopanib—MAP3K2—testis—prostate cancer	0.000255	0.00391	CbGeAlD
Pazopanib—RIOK2—lymph node—prostate cancer	0.000252	0.00385	CbGeAlD
Pazopanib—BMPR1B—lymph node—prostate cancer	0.000249	0.00381	CbGeAlD
Pazopanib—KIT—renal system—prostate cancer	0.000244	0.00373	CbGeAlD
Pazopanib—SLCO1B1—renal system—prostate cancer	0.000242	0.00371	CbGeAlD
Pazopanib—FGF1—testis—prostate cancer	0.000241	0.00368	CbGeAlD
Pazopanib—KIT—urethra—prostate cancer	0.00024	0.00367	CbGeAlD
Pazopanib—LCK—testis—prostate cancer	0.000239	0.00366	CbGeAlD
Pazopanib—PDGFRB—renal system—prostate cancer	0.000238	0.00365	CbGeAlD
Pazopanib—PDGFRB—urethra—prostate cancer	0.000234	0.00358	CbGeAlD
Pazopanib—STK10—bone marrow—prostate cancer	0.000233	0.00357	CbGeAlD
Pazopanib—TAOK3—bone marrow—prostate cancer	0.000232	0.00355	CbGeAlD
Pazopanib—FGFR2—Estradiol—Conjugated Estrogens—prostate cancer	0.000231	0.107	CbGdCrCtD
Pazopanib—FGFR2—testis—prostate cancer	0.000227	0.00348	CbGeAlD
Pazopanib—STK36—lymph node—prostate cancer	0.000226	0.00346	CbGeAlD
Pazopanib—PI4KB—lymph node—prostate cancer	0.000222	0.0034	CbGeAlD
Pazopanib—LIMK2—lymph node—prostate cancer	0.000218	0.00334	CbGeAlD
Pazopanib—FLT1—testis—prostate cancer	0.000211	0.00322	CbGeAlD
Pazopanib—KDR—bone marrow—prostate cancer	0.000208	0.00319	CbGeAlD
Pazopanib—EPHB6—testis—prostate cancer	0.000208	0.00319	CbGeAlD
Pazopanib—CSF1R—bone marrow—prostate cancer	0.000203	0.00311	CbGeAlD
Pazopanib—STK10—testis—prostate cancer	0.000199	0.00305	CbGeAlD
Pazopanib—TAOK3—testis—prostate cancer	0.000199	0.00304	CbGeAlD
Pazopanib—PDGFRA—testis—prostate cancer	0.000197	0.00302	CbGeAlD
Pazopanib—ABCG2—prostate gland—prostate cancer	0.000197	0.00301	CbGeAlD
Pazopanib—FLT4—lymph node—prostate cancer	0.000196	0.003	CbGeAlD
Pazopanib—PIP4K2C—lymph node—prostate cancer	0.000195	0.00299	CbGeAlD
Pazopanib—FGFR2—Estradiol—Ethinyl Estradiol—prostate cancer	0.000194	0.0896	CbGdCrCtD
Pazopanib—FGFR1—lymph node—prostate cancer	0.000194	0.00296	CbGeAlD
Pazopanib—MAP3K2—lymph node—prostate cancer	0.000185	0.00283	CbGeAlD
Pazopanib—KIT—bone marrow—prostate cancer	0.000185	0.00282	CbGeAlD
Pazopanib—PDGFRB—bone marrow—prostate cancer	0.00018	0.00276	CbGeAlD
Pazopanib—PLK4—Fulvestrant—Estradiol—prostate cancer	0.000178	0.0822	CbGdCrCtD
Pazopanib—KDR—testis—prostate cancer	0.000178	0.00272	CbGeAlD
Pazopanib—MAP2K5—testis—prostate cancer	0.000178	0.00272	CbGeAlD
Pazopanib—FGF1—lymph node—prostate cancer	0.000174	0.00267	CbGeAlD
Pazopanib—CSF1R—testis—prostate cancer	0.000174	0.00266	CbGeAlD
Pazopanib—LCK—lymph node—prostate cancer	0.000173	0.00265	CbGeAlD
Pazopanib—ABCG2—seminal vesicle—prostate cancer	0.000166	0.00254	CbGeAlD
Pazopanib—KIT—testis—prostate cancer	0.000158	0.00241	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—prostate cancer	0.000157	0.0724	CbGdCrCtD
Pazopanib—PDGFRB—testis—prostate cancer	0.000154	0.00236	CbGeAlD
Pazopanib—FLT1—lymph node—prostate cancer	0.000153	0.00234	CbGeAlD
Pazopanib—EPHB6—lymph node—prostate cancer	0.000151	0.00231	CbGeAlD
Pazopanib—STK10—lymph node—prostate cancer	0.000144	0.00221	CbGeAlD
Pazopanib—TAOK3—lymph node—prostate cancer	0.000144	0.0022	CbGeAlD
Pazopanib—PDGFRA—lymph node—prostate cancer	0.000143	0.00219	CbGeAlD
Pazopanib—CYP2C8—renal system—prostate cancer	0.000138	0.00211	CbGeAlD
Pazopanib—ABCG2—urethra—prostate cancer	0.000132	0.00201	CbGeAlD
Pazopanib—KDR—lymph node—prostate cancer	0.000129	0.00197	CbGeAlD
Pazopanib—MAP2K5—lymph node—prostate cancer	0.000129	0.00197	CbGeAlD
Pazopanib—CYP1A2—renal system—prostate cancer	0.000129	0.00197	CbGeAlD
Pazopanib—CSF1R—lymph node—prostate cancer	0.000126	0.00193	CbGeAlD
Pazopanib—KIT—lymph node—prostate cancer	0.000114	0.00175	CbGeAlD
Pazopanib—PDGFRB—lymph node—prostate cancer	0.000112	0.00171	CbGeAlD
Pazopanib—ABCG2—bone marrow—prostate cancer	0.000101	0.00155	CbGeAlD
Pazopanib—ABCB1—prostate gland—prostate cancer	9.69e-05	0.00148	CbGeAlD
Pazopanib—CYP3A4—renal system—prostate cancer	9.33e-05	0.00143	CbGeAlD
Pazopanib—CYP2D6—renal system—prostate cancer	9.18e-05	0.00141	CbGeAlD
Pazopanib—CYP2C8—testis—prostate cancer	8.91e-05	0.00136	CbGeAlD
Pazopanib—ABCG2—testis—prostate cancer	8.66e-05	0.00133	CbGeAlD
Pazopanib—ABCB1—seminal vesicle—prostate cancer	8.2e-05	0.00125	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—prostate cancer	8.18e-05	0.0378	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—prostate cancer	8.18e-05	0.0378	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—prostate cancer	7.57e-05	0.0349	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—prostate cancer	7.57e-05	0.0349	CbGdCrCtD
Pazopanib—ABCB1—epithelium—prostate cancer	7.12e-05	0.00109	CbGeAlD
Pazopanib—ABCB1—renal system—prostate cancer	6.61e-05	0.00101	CbGeAlD
Pazopanib—ABCB1—urethra—prostate cancer	6.49e-05	0.000993	CbGeAlD
Pazopanib—ABCG2—lymph node—prostate cancer	6.28e-05	0.000961	CbGeAlD
Pazopanib—CYP2D6—testis—prostate cancer	5.94e-05	0.000908	CbGeAlD
Pazopanib—SH2B3—Betamethasone—Prednisone—prostate cancer	5.48e-05	0.0253	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisone—prostate cancer	5.48e-05	0.0253	CbGdCrCtD
Pazopanib—ABCB1—bone marrow—prostate cancer	4.99e-05	0.000764	CbGeAlD
Pazopanib—ABCB1—testis—prostate cancer	4.27e-05	0.000653	CbGeAlD
Pazopanib—ABCB1—lymph node—prostate cancer	3.09e-05	0.000474	CbGeAlD
Pazopanib—Chest pain—Capecitabine—prostate cancer	2.47e-05	0.00021	CcSEcCtD
Pazopanib—Arthralgia—Capecitabine—prostate cancer	2.47e-05	0.00021	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—prostate cancer	2.47e-05	0.000209	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.45e-05	0.000208	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—prostate cancer	2.45e-05	0.000208	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—prostate cancer	2.45e-05	0.000208	CcSEcCtD
Pazopanib—Oedema—Docetaxel—prostate cancer	2.45e-05	0.000208	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—prostate cancer	2.44e-05	0.000207	CcSEcCtD
Pazopanib—Vision blurred—Prednisone—prostate cancer	2.44e-05	0.000207	CcSEcCtD
Pazopanib—Infection—Docetaxel—prostate cancer	2.43e-05	0.000206	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—prostate cancer	2.43e-05	0.000206	CcSEcCtD
Pazopanib—Diarrhoea—Mitoxantrone—prostate cancer	2.42e-05	0.000206	CcSEcCtD
Pazopanib—Dry mouth—Capecitabine—prostate cancer	2.42e-05	0.000205	CcSEcCtD
Pazopanib—Vomiting—Estradiol—prostate cancer	2.42e-05	0.000205	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—prostate cancer	2.41e-05	0.000204	CcSEcCtD
Pazopanib—Shock—Docetaxel—prostate cancer	2.41e-05	0.000204	CcSEcCtD
Pazopanib—Nervous system disorder—Docetaxel—prostate cancer	2.4e-05	0.000204	CcSEcCtD
Pazopanib—Thrombocytopenia—Docetaxel—prostate cancer	2.4e-05	0.000203	CcSEcCtD
Pazopanib—Rash—Estradiol—prostate cancer	2.39e-05	0.000203	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—prostate cancer	2.39e-05	0.000203	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—prostate cancer	2.39e-05	0.000203	CcSEcCtD
Pazopanib—Dermatitis—Estradiol—prostate cancer	2.39e-05	0.000203	CcSEcCtD
Pazopanib—Anaemia—Prednisone—prostate cancer	2.39e-05	0.000203	CcSEcCtD
Pazopanib—Headache—Estradiol—prostate cancer	2.38e-05	0.000202	CcSEcCtD
Pazopanib—Skin disorder—Docetaxel—prostate cancer	2.38e-05	0.000202	CcSEcCtD
Pazopanib—Oedema—Capecitabine—prostate cancer	2.37e-05	0.000201	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—prostate cancer	2.36e-05	0.000201	CcSEcCtD
Pazopanib—Infection—Capecitabine—prostate cancer	2.35e-05	0.0002	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Anorexia—Docetaxel—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Shock—Capecitabine—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—prostate cancer	2.33e-05	0.000198	CcSEcCtD
Pazopanib—Nervous system disorder—Capecitabine—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Pazopanib—Thrombocytopenia—Capecitabine—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Pazopanib—Syncope—Prednisone—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—prostate cancer	2.31e-05	0.000196	CcSEcCtD
Pazopanib—Skin disorder—Capecitabine—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—prostate cancer	2.29e-05	0.000195	CcSEcCtD
Pazopanib—Hyperhidrosis—Capecitabine—prostate cancer	2.29e-05	0.000194	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—prostate cancer	2.29e-05	0.000194	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—prostate cancer	2.28e-05	0.000194	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—prostate cancer	2.28e-05	0.000194	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—prostate cancer	2.28e-05	0.000193	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisone—prostate cancer	2.27e-05	0.000193	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Pazopanib—Anorexia—Capecitabine—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Pazopanib—Nausea—Estradiol—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Pazopanib—Vomiting—Mitoxantrone—prostate cancer	2.25e-05	0.000191	CcSEcCtD
Pazopanib—Hypertension—Prednisone—prostate cancer	2.23e-05	0.00019	CcSEcCtD
Pazopanib—Rash—Mitoxantrone—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Pazopanib—Dermatitis—Mitoxantrone—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Pazopanib—Headache—Mitoxantrone—prostate cancer	2.22e-05	0.000188	CcSEcCtD
Pazopanib—Insomnia—Docetaxel—prostate cancer	2.21e-05	0.000188	CcSEcCtD
Pazopanib—Myalgia—Prednisone—prostate cancer	2.2e-05	0.000187	CcSEcCtD
Pazopanib—Arthralgia—Prednisone—prostate cancer	2.2e-05	0.000187	CcSEcCtD
Pazopanib—Paraesthesia—Docetaxel—prostate cancer	2.2e-05	0.000187	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Pazopanib—Dyspnoea—Docetaxel—prostate cancer	2.18e-05	0.000185	CcSEcCtD
Pazopanib—Somnolence—Docetaxel—prostate cancer	2.17e-05	0.000185	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Pazopanib—Flushing—Epirubicin—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Pazopanib—Dyspepsia—Docetaxel—prostate cancer	2.15e-05	0.000183	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—prostate cancer	2.15e-05	0.000182	CcSEcCtD
Pazopanib—Insomnia—Capecitabine—prostate cancer	2.14e-05	0.000182	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—prostate cancer	2.14e-05	0.000182	CcSEcCtD
Pazopanib—Paraesthesia—Capecitabine—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Pazopanib—Decreased appetite—Docetaxel—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Asthenia—Etoposide—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Dyspnoea—Capecitabine—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Oedema—Prednisone—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Fatigue—Docetaxel—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Pazopanib—Nausea—Mitoxantrone—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Pazopanib—Infection—Prednisone—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—prostate cancer	2.09e-05	0.000178	CcSEcCtD
Pazopanib—Pain—Docetaxel—prostate cancer	2.09e-05	0.000178	CcSEcCtD
Pazopanib—Dyspepsia—Capecitabine—prostate cancer	2.09e-05	0.000177	CcSEcCtD
Pazopanib—Chills—Epirubicin—prostate cancer	2.08e-05	0.000177	CcSEcCtD
Pazopanib—Pruritus—Etoposide—prostate cancer	2.08e-05	0.000177	CcSEcCtD
Pazopanib—Shock—Prednisone—prostate cancer	2.08e-05	0.000176	CcSEcCtD
Pazopanib—Nervous system disorder—Prednisone—prostate cancer	2.07e-05	0.000176	CcSEcCtD
Pazopanib—Decreased appetite—Capecitabine—prostate cancer	2.06e-05	0.000175	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—prostate cancer	2.05e-05	0.000174	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—prostate cancer	2.05e-05	0.000174	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.04e-05	0.000174	CcSEcCtD
Pazopanib—Fatigue—Capecitabine—prostate cancer	2.04e-05	0.000173	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisone—prostate cancer	2.04e-05	0.000173	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—prostate cancer	2.03e-05	0.000173	CcSEcCtD
Pazopanib—Pain—Capecitabine—prostate cancer	2.03e-05	0.000172	CcSEcCtD
Pazopanib—Erythema—Epirubicin—prostate cancer	2.02e-05	0.000172	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—prostate cancer	2.02e-05	0.000172	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—prostate cancer	2.01e-05	0.000171	CcSEcCtD
Pazopanib—Anorexia—Prednisone—prostate cancer	2.01e-05	0.000171	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—prostate cancer	2.01e-05	0.000171	CcSEcCtD
Pazopanib—Gastrointestinal pain—Docetaxel—prostate cancer	2e-05	0.00017	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—prostate cancer	1.98e-05	0.000168	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—prostate cancer	1.95e-05	0.000166	CcSEcCtD
Pazopanib—Dizziness—Etoposide—prostate cancer	1.95e-05	0.000165	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—prostate cancer	1.94e-05	0.000165	CcSEcCtD
Pazopanib—Gastrointestinal pain—Capecitabine—prostate cancer	1.94e-05	0.000164	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—prostate cancer	1.94e-05	0.000164	CcSEcCtD
Pazopanib—Abdominal pain—Docetaxel—prostate cancer	1.93e-05	0.000164	CcSEcCtD
Pazopanib—Chills—Doxorubicin—prostate cancer	1.93e-05	0.000164	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Pazopanib—Insomnia—Prednisone—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—prostate cancer	1.9e-05	0.000161	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—prostate cancer	1.89e-05	0.000161	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—prostate cancer	1.88e-05	0.00016	CcSEcCtD
Pazopanib—Abdominal pain—Capecitabine—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Pazopanib—Vomiting—Etoposide—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Pazopanib—Dyspepsia—Prednisone—prostate cancer	1.86e-05	0.000158	CcSEcCtD
Pazopanib—Rash—Etoposide—prostate cancer	1.86e-05	0.000158	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Pazopanib—Headache—Etoposide—prostate cancer	1.84e-05	0.000157	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—prostate cancer	1.84e-05	0.000157	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—prostate cancer	1.83e-05	0.000156	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—prostate cancer	1.83e-05	0.000156	CcSEcCtD
Pazopanib—Fatigue—Prednisone—prostate cancer	1.82e-05	0.000154	CcSEcCtD
Pazopanib—Syncope—Epirubicin—prostate cancer	1.81e-05	0.000154	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—prostate cancer	1.81e-05	0.000154	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—prostate cancer	1.8e-05	0.000153	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Pazopanib—Cough—Epirubicin—prostate cancer	1.76e-05	0.00015	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—prostate cancer	1.76e-05	0.00015	CcSEcCtD
Pazopanib—Asthenia—Docetaxel—prostate cancer	1.76e-05	0.000149	CcSEcCtD
Pazopanib—Nausea—Etoposide—prostate cancer	1.75e-05	0.000148	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—prostate cancer	1.75e-05	0.000148	CcSEcCtD
Pazopanib—Pruritus—Docetaxel—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—prostate cancer	1.73e-05	0.000146	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Pazopanib—Asthenia—Capecitabine—prostate cancer	1.7e-05	0.000144	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—prostate cancer	1.68e-05	0.000143	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—prostate cancer	1.68e-05	0.000142	CcSEcCtD
Pazopanib—Pruritus—Capecitabine—prostate cancer	1.68e-05	0.000142	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—prostate cancer	1.67e-05	0.000142	CcSEcCtD
Pazopanib—Diarrhoea—Docetaxel—prostate cancer	1.67e-05	0.000142	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—prostate cancer	1.67e-05	0.000142	CcSEcCtD
Pazopanib—Oedema—Epirubicin—prostate cancer	1.65e-05	0.00014	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—prostate cancer	1.64e-05	0.00014	CcSEcCtD
Pazopanib—Infection—Epirubicin—prostate cancer	1.64e-05	0.000139	CcSEcCtD
Pazopanib—Cough—Doxorubicin—prostate cancer	1.63e-05	0.000139	CcSEcCtD
Pazopanib—Shock—Epirubicin—prostate cancer	1.62e-05	0.000138	CcSEcCtD
Pazopanib—Diarrhoea—Capecitabine—prostate cancer	1.62e-05	0.000138	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Pazopanib—Dizziness—Docetaxel—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—prostate cancer	1.6e-05	0.000136	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—prostate cancer	1.6e-05	0.000135	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—prostate cancer	1.59e-05	0.000135	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—prostate cancer	1.59e-05	0.000135	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—prostate cancer	1.59e-05	0.000135	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—prostate cancer	1.57e-05	0.000134	CcSEcCtD
Pazopanib—Dizziness—Capecitabine—prostate cancer	1.57e-05	0.000133	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—prostate cancer	1.56e-05	0.000132	CcSEcCtD
Pazopanib—Vomiting—Docetaxel—prostate cancer	1.56e-05	0.000132	CcSEcCtD
Pazopanib—Rash—Docetaxel—prostate cancer	1.54e-05	0.000131	CcSEcCtD
Pazopanib—Dermatitis—Docetaxel—prostate cancer	1.54e-05	0.000131	CcSEcCtD
Pazopanib—Headache—Docetaxel—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Pazopanib—Infection—Doxorubicin—prostate cancer	1.52e-05	0.000129	CcSEcCtD
Pazopanib—Asthenia—Prednisone—prostate cancer	1.51e-05	0.000129	CcSEcCtD
Pazopanib—Vomiting—Capecitabine—prostate cancer	1.51e-05	0.000128	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.5e-05	0.000128	CcSEcCtD
Pazopanib—Shock—Doxorubicin—prostate cancer	1.5e-05	0.000128	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—prostate cancer	1.5e-05	0.000127	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Pazopanib—Rash—Capecitabine—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Pazopanib—Pruritus—Prednisone—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Pazopanib—Dermatitis—Capecitabine—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Pazopanib—Headache—Capecitabine—prostate cancer	1.48e-05	0.000126	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—prostate cancer	1.48e-05	0.000126	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—prostate cancer	1.48e-05	0.000126	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—prostate cancer	1.47e-05	0.000125	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—prostate cancer	1.47e-05	0.000125	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—prostate cancer	1.46e-05	0.000124	CcSEcCtD
Pazopanib—Nausea—Docetaxel—prostate cancer	1.45e-05	0.000123	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—prostate cancer	1.45e-05	0.000123	CcSEcCtD
Pazopanib—Diarrhoea—Prednisone—prostate cancer	1.44e-05	0.000123	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—prostate cancer	1.43e-05	0.000122	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.42e-05	0.000121	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—prostate cancer	1.42e-05	0.000121	CcSEcCtD
Pazopanib—Pain—Epirubicin—prostate cancer	1.41e-05	0.00012	CcSEcCtD
Pazopanib—Nausea—Capecitabine—prostate cancer	1.41e-05	0.000119	CcSEcCtD
Pazopanib—Dizziness—Prednisone—prostate cancer	1.4e-05	0.000118	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.39e-05	0.000118	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—prostate cancer	1.38e-05	0.000117	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—prostate cancer	1.36e-05	0.000116	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—prostate cancer	1.35e-05	0.000115	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Pazopanib—Vomiting—Prednisone—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Pazopanib—Rash—Prednisone—prostate cancer	1.33e-05	0.000113	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—prostate cancer	1.33e-05	0.000113	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—prostate cancer	1.33e-05	0.000113	CcSEcCtD
Pazopanib—Headache—Prednisone—prostate cancer	1.32e-05	0.000112	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.32e-05	0.000112	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—prostate cancer	1.32e-05	0.000112	CcSEcCtD
Pazopanib—Pain—Doxorubicin—prostate cancer	1.31e-05	0.000111	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—prostate cancer	1.3e-05	0.000111	CcSEcCtD
Pazopanib—Nausea—Prednisone—prostate cancer	1.25e-05	0.000106	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.25e-05	0.000106	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—prostate cancer	1.21e-05	0.000102	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—prostate cancer	1.18e-05	0.000101	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—prostate cancer	1.17e-05	9.91e-05	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—prostate cancer	1.13e-05	9.59e-05	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—prostate cancer	1.1e-05	9.3e-05	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—prostate cancer	1.09e-05	9.27e-05	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—prostate cancer	1.08e-05	9.17e-05	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—prostate cancer	1.05e-05	8.91e-05	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—prostate cancer	1.04e-05	8.87e-05	CcSEcCtD
Pazopanib—Rash—Epirubicin—prostate cancer	1.04e-05	8.83e-05	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—prostate cancer	1.04e-05	8.83e-05	CcSEcCtD
Pazopanib—Headache—Epirubicin—prostate cancer	1.03e-05	8.78e-05	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—prostate cancer	1.01e-05	8.57e-05	CcSEcCtD
Pazopanib—Nausea—Epirubicin—prostate cancer	9.8e-06	8.32e-05	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—prostate cancer	9.71e-06	8.24e-05	CcSEcCtD
Pazopanib—Rash—Doxorubicin—prostate cancer	9.63e-06	8.17e-05	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—prostate cancer	9.62e-06	8.17e-05	CcSEcCtD
Pazopanib—Headache—Doxorubicin—prostate cancer	9.57e-06	8.12e-05	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—prostate cancer	9.07e-06	7.7e-05	CcSEcCtD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—prostate cancer	4.27e-07	3.5e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—prostate cancer	4.27e-07	3.5e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—prostate cancer	4.27e-07	3.5e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—LPL—prostate cancer	4.27e-07	3.49e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—prostate cancer	4.26e-07	3.49e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—prostate cancer	4.26e-07	3.49e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—prostate cancer	4.25e-07	3.48e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—prostate cancer	4.25e-07	3.48e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—prostate cancer	4.23e-07	3.46e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—prostate cancer	4.22e-07	3.46e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—prostate cancer	4.22e-07	3.46e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—prostate cancer	4.22e-07	3.45e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—prostate cancer	4.22e-07	3.45e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—prostate cancer	4.21e-07	3.45e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—prostate cancer	4.21e-07	3.45e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—prostate cancer	4.21e-07	3.44e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ACHE—prostate cancer	4.2e-07	3.44e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—prostate cancer	4.2e-07	3.44e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GGT1—prostate cancer	4.2e-07	3.44e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—prostate cancer	4.19e-07	3.43e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—prostate cancer	4.19e-07	3.43e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—prostate cancer	4.18e-07	3.42e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—prostate cancer	4.17e-07	3.42e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—prostate cancer	4.16e-07	3.41e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JAK2—prostate cancer	4.16e-07	3.4e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.16e-07	3.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TYMS—prostate cancer	4.14e-07	3.39e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—prostate cancer	4.14e-07	3.39e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NCOA1—prostate cancer	4.14e-07	3.39e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—prostate cancer	4.13e-07	3.38e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—prostate cancer	4.13e-07	3.38e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—prostate cancer	4.12e-07	3.37e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1A1—prostate cancer	4.12e-07	3.37e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—prostate cancer	4.11e-07	3.36e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—prostate cancer	4.1e-07	3.36e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—prostate cancer	4.1e-07	3.35e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ERCC2—prostate cancer	4.09e-07	3.35e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP19A1—prostate cancer	4.08e-07	3.34e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—prostate cancer	4.07e-07	3.33e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CAV1—prostate cancer	4.07e-07	3.33e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—prostate cancer	4.06e-07	3.32e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—prostate cancer	4.05e-07	3.32e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—prostate cancer	4.05e-07	3.32e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—prostate cancer	4.05e-07	3.32e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—prostate cancer	4.05e-07	3.32e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.04e-07	3.31e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—prostate cancer	4.04e-07	3.31e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—prostate cancer	4.02e-07	3.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PRKACB—prostate cancer	4.02e-07	3.29e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—LPL—prostate cancer	4.02e-07	3.29e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—prostate cancer	4.02e-07	3.29e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—prostate cancer	4e-07	3.28e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.98e-07	3.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—prostate cancer	3.97e-07	3.25e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—prostate cancer	3.96e-07	3.24e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—prostate cancer	3.95e-07	3.24e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—prostate cancer	3.95e-07	3.23e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—prostate cancer	3.94e-07	3.23e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—RXRA—prostate cancer	3.94e-07	3.23e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—prostate cancer	3.93e-07	3.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—prostate cancer	3.92e-07	3.21e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—prostate cancer	3.92e-07	3.21e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—prostate cancer	3.91e-07	3.2e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—prostate cancer	3.9e-07	3.19e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—prostate cancer	3.89e-07	3.19e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.89e-07	3.18e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—prostate cancer	3.88e-07	3.18e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.88e-07	3.18e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—prostate cancer	3.86e-07	3.16e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ERCC2—prostate cancer	3.85e-07	3.15e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—prostate cancer	3.85e-07	3.15e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—prostate cancer	3.84e-07	3.15e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	3.84e-07	3.14e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	3.84e-07	3.14e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—prostate cancer	3.83e-07	3.14e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.83e-07	3.14e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—prostate cancer	3.83e-07	3.13e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	3.8e-07	3.11e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	3.8e-07	3.11e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—prostate cancer	3.79e-07	3.11e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—COMT—prostate cancer	3.79e-07	3.11e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—prostate cancer	3.79e-07	3.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NCOA2—prostate cancer	3.79e-07	3.11e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—prostate cancer	3.79e-07	3.1e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—prostate cancer	3.78e-07	3.09e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—prostate cancer	3.77e-07	3.09e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARA—prostate cancer	3.77e-07	3.09e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—prostate cancer	3.76e-07	3.08e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—prostate cancer	3.74e-07	3.06e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—prostate cancer	3.72e-07	3.05e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—prostate cancer	3.72e-07	3.05e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ITPR1—prostate cancer	3.72e-07	3.04e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—prostate cancer	3.71e-07	3.04e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—prostate cancer	3.71e-07	3.03e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—prostate cancer	3.71e-07	3.03e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—prostate cancer	3.71e-07	3.03e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.65e-07	2.99e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—prostate cancer	3.63e-07	2.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—prostate cancer	3.63e-07	2.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—prostate cancer	3.63e-07	2.97e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	3.62e-07	2.97e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—prostate cancer	3.62e-07	2.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.62e-07	2.96e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—prostate cancer	3.58e-07	2.93e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARA—prostate cancer	3.55e-07	2.91e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CAV1—prostate cancer	3.54e-07	2.9e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—prostate cancer	3.54e-07	2.89e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—prostate cancer	3.54e-07	2.89e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.53e-07	2.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—prostate cancer	3.53e-07	2.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	3.52e-07	2.89e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—prostate cancer	3.52e-07	2.88e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TYMS—prostate cancer	3.51e-07	2.87e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—INS—prostate cancer	3.51e-07	2.87e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—prostate cancer	3.5e-07	2.87e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—prostate cancer	3.5e-07	2.87e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NQO1—prostate cancer	3.49e-07	2.86e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—prostate cancer	3.47e-07	2.84e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—prostate cancer	3.46e-07	2.84e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—prostate cancer	3.46e-07	2.83e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	3.46e-07	2.83e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—prostate cancer	3.45e-07	2.83e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TH—prostate cancer	3.44e-07	2.82e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—prostate cancer	3.44e-07	2.81e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—prostate cancer	3.44e-07	2.81e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—prostate cancer	3.43e-07	2.81e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—prostate cancer	3.42e-07	2.8e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—prostate cancer	3.41e-07	2.79e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—LPL—prostate cancer	3.41e-07	2.79e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—prostate cancer	3.4e-07	2.79e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—prostate cancer	3.38e-07	2.77e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.35e-07	2.74e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CAV1—prostate cancer	3.34e-07	2.73e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—prostate cancer	3.34e-07	2.73e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	3.33e-07	2.73e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—prostate cancer	3.3e-07	2.7e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1A1—prostate cancer	3.29e-07	2.69e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—prostate cancer	3.29e-07	2.69e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	3.26e-07	2.67e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ERCC2—prostate cancer	3.26e-07	2.67e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—prostate cancer	3.26e-07	2.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—prostate cancer	3.25e-07	2.66e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GGT1—prostate cancer	3.24e-07	2.66e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—prostate cancer	3.23e-07	2.64e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—prostate cancer	3.23e-07	2.64e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—prostate cancer	3.22e-07	2.64e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—prostate cancer	3.2e-07	2.62e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NCOA1—prostate cancer	3.2e-07	2.62e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—prostate cancer	3.17e-07	2.6e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—prostate cancer	3.16e-07	2.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.15e-07	2.58e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—prostate cancer	3.11e-07	2.55e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—prostate cancer	3.08e-07	2.52e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NOS3—prostate cancer	3.08e-07	2.52e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—prostate cancer	3.07e-07	2.51e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—INS—prostate cancer	3.06e-07	2.5e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—prostate cancer	3.05e-07	2.5e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—prostate cancer	3.04e-07	2.49e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.04e-07	2.49e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—prostate cancer	3.04e-07	2.49e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RXRA—prostate cancer	3.04e-07	2.49e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—prostate cancer	3.01e-07	2.47e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARA—prostate cancer	3.01e-07	2.46e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	3e-07	2.46e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—prostate cancer	2.99e-07	2.45e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—prostate cancer	2.96e-07	2.42e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—prostate cancer	2.95e-07	2.41e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—prostate cancer	2.94e-07	2.4e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—COMT—prostate cancer	2.93e-07	2.4e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—prostate cancer	2.93e-07	2.4e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—prostate cancer	2.91e-07	2.39e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—prostate cancer	2.9e-07	2.38e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—INS—prostate cancer	2.88e-07	2.36e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—prostate cancer	2.87e-07	2.35e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ITPR1—prostate cancer	2.87e-07	2.35e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—prostate cancer	2.84e-07	2.33e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—prostate cancer	2.84e-07	2.32e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—prostate cancer	2.84e-07	2.32e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—prostate cancer	2.84e-07	2.32e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CAV1—prostate cancer	2.83e-07	2.32e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—prostate cancer	2.83e-07	2.32e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—prostate cancer	2.82e-07	2.31e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—prostate cancer	2.81e-07	2.3e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—prostate cancer	2.81e-07	2.3e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—prostate cancer	2.79e-07	2.28e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—prostate cancer	2.77e-07	2.27e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—prostate cancer	2.73e-07	2.23e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	2.72e-07	2.23e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMS—prostate cancer	2.71e-07	2.22e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.7e-07	2.21e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—prostate cancer	2.69e-07	2.2e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NOS3—prostate cancer	2.68e-07	2.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—prostate cancer	2.68e-07	2.19e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.67e-07	2.19e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—prostate cancer	2.66e-07	2.17e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LPL—prostate cancer	2.63e-07	2.15e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—prostate cancer	2.62e-07	2.15e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—prostate cancer	2.6e-07	2.13e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.58e-07	2.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.54e-07	2.08e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NOS3—prostate cancer	2.53e-07	2.07e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ERCC2—prostate cancer	2.52e-07	2.06e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—prostate cancer	2.47e-07	2.03e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—prostate cancer	2.46e-07	2.01e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—prostate cancer	2.45e-07	2.01e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—prostate cancer	2.45e-07	2.01e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	2.45e-07	2.01e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—INS—prostate cancer	2.44e-07	2e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—prostate cancer	2.41e-07	1.97e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—prostate cancer	2.4e-07	1.96e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—prostate cancer	2.39e-07	1.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—prostate cancer	2.37e-07	1.94e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—prostate cancer	2.34e-07	1.92e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.33e-07	1.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—prostate cancer	2.33e-07	1.91e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARA—prostate cancer	2.32e-07	1.9e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—prostate cancer	2.31e-07	1.89e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—prostate cancer	2.28e-07	1.87e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.27e-07	1.85e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CAV1—prostate cancer	2.18e-07	1.79e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NOS3—prostate cancer	2.14e-07	1.75e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—prostate cancer	2.14e-07	1.75e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—prostate cancer	2.13e-07	1.75e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—prostate cancer	2.04e-07	1.67e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—prostate cancer	2.01e-07	1.65e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.99e-07	1.63e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.97e-07	1.62e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—prostate cancer	1.97e-07	1.61e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—prostate cancer	1.96e-07	1.6e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—prostate cancer	1.92e-07	1.57e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—INS—prostate cancer	1.88e-07	1.54e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—prostate cancer	1.84e-07	1.51e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.75e-07	1.43e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.73e-07	1.42e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—prostate cancer	1.71e-07	1.4e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NOS3—prostate cancer	1.65e-07	1.35e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—prostate cancer	1.63e-07	1.33e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.52e-07	1.25e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—prostate cancer	1.51e-07	1.24e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—prostate cancer	1.51e-07	1.23e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.42e-07	1.16e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—prostate cancer	1.41e-07	1.16e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—prostate cancer	1.32e-07	1.08e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—prostate cancer	1.26e-07	1.03e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—prostate cancer	1.23e-07	1.01e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.2e-07	9.86e-07	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—prostate cancer	1.16e-07	9.5e-07	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—prostate cancer	9.83e-08	8.05e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—prostate cancer	9.29e-08	7.61e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—prostate cancer	7.59e-08	6.21e-07	CbGpPWpGaD
